{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:33:54Z","timestamp":1760056434490,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ncl.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T18:27:27Z","timestamp":1595269647000},"page":"661-678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammatory Myopathies"],"prefix":"10.1016","volume":"38","author":[{"given":"Suur","family":"Biliciler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ncl.2020.05.001_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ncl.2020.05.001_bib2","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ncl.2020.05.001_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12016-017-8652-1","article-title":"Cutaneous manifestations of dermatomyositis: a comprehensive review","volume":"53","author":"Mainetti","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.ncl.2020.05.001_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4103\/0019-5154.100486","article-title":"Clinical presentation and evaluation of dermatomyositis","volume":"57","author":"Marvi","year":"2012","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.ncl.2020.05.001_bib5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3389\/fneur.2019.00554","article-title":"Biomarkers in inflammatory myopathies-an expanded definition","volume":"10","author":"Benveniste","year":"2019","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2020.05.001_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.ncl.2020.05.001_bib7","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ncl.2020.05.001_bib8","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2020.05.001_bib9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.ncl.2020.05.001_bib10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/WCO.0000000000000740","article-title":"Classification of idiopathic inflammatory myopathies: pathology perspectives","volume":"32","author":"Tanboon","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2020.05.001_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.ncl.2020.05.001_bib12","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ncl.2020.05.001_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-gamma antibody and cancer-associated myositis: A clinicohistopathologic study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"issue":"27","key":"10.1016\/j.ncl.2020.05.001_bib14","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A\u00a0controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ncl.2020.05.001_bib15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2020.05.001_bib16","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.nmd.2018.06.005","article-title":"Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center","volume":"28","author":"Felice","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.ncl.2020.05.001_bib17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2020.05.001_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A\u00a0controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2020.05.001_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00005792-199307000-00002","article-title":"The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy","volume":"72","author":"Leff","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ncl.2020.05.001_bib20","doi-asserted-by":"crossref","first-page":"100204","DOI":"10.1016\/j.ensci.2019.100204","article-title":"Effect of intravenous immunoglobulin therapy on anti-NT5C1A antibody-positive inclusion body myositis after successful treatment of hepatitis C: A case report","volume":"16","author":"Takamiya","year":"2019","journal-title":"eNeurologicalSci"},{"issue":"9","key":"10.1016\/j.ncl.2020.05.001_bib21","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","article-title":"Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis","volume":"57","author":"Muscle Study","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2020.05.001_bib22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","article-title":"Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study","volume":"61","author":"Lindberg","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.ncl.2020.05.001_bib23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol"},{"issue":"Pt 6","key":"10.1016\/j.ncl.2020.05.001_bib24","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ncl.2020.05.001_bib25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10072-011-0657-6","article-title":"Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis","volume":"32","author":"Sancricca","year":"2011","journal-title":"Neurol Sci"},{"issue":"1\u20132","key":"10.1016\/j.ncl.2020.05.001_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","article-title":"The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study","volume":"334","author":"Kosmidis","year":"2013","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2020.05.001_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CCRep.S10200","article-title":"Balloon dilation in sporadic inclusion body myositis patients with Dysphagia","volume":"6","author":"Murata","year":"2013","journal-title":"Clin Med Insights Case Rep"},{"issue":"4","key":"10.1016\/j.ncl.2020.05.001_bib28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4065\/82.4.441","article-title":"Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients","volume":"82","author":"Oh","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ncl.2020.05.001_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2017.07.031","article-title":"Botulinum toxin alleviates dysphagia of patients with inclusion body myositis","volume":"380","author":"Schrey","year":"2017","journal-title":"J\u00a0Neurol Sci"},{"issue":"4","key":"10.1016\/j.ncl.2020.05.001_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40674-018-0113-3","article-title":"Exercise in myositis","volume":"4","author":"Alexanderson","year":"2018","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"4","key":"10.1016\/j.ncl.2020.05.001_bib31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CND.0b013e3181a23c86","article-title":"Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis","volume":"10","author":"Johnson","year":"2009","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"issue":"6","key":"10.1016\/j.ncl.2020.05.001_bib32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/BOR.0000000000000536","article-title":"The clinico-serological spectrum of overlap myositis","volume":"30","author":"Fredi","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.ncl.2020.05.001_bib33","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s10067-018-4031-4","article-title":"The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy","volume":"37","author":"Zhang","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ncl.2020.05.001_bib34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2169\/internalmedicine.9363-17","article-title":"Dropped head syndrome and the presence of rimmed vacuoles in a muscle biopsy in scleroderma-polymyositis overlap syndrome associated with anti-ku antibody","volume":"57","author":"Yoshida","year":"2018","journal-title":"Intern Med"},{"issue":"23","key":"10.1016\/j.ncl.2020.05.001_bib35","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ncl.2020.05.001_bib36","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/ene.12989","article-title":"Is deltoid muscle biopsy useful in isolated camptocormia? A prospective study","volume":"23","author":"Chanson","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2020.05.001_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.ncl.2020.05.001_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2020.05.001_bib39","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ncl.2020.05.001_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/art.11484","article-title":"Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy","volume":"50","author":"Kao","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.ncl.2020.05.001_bib41","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"Pt 8","key":"10.1016\/j.ncl.2020.05.001_bib42","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ncl.2020.05.001_bib43","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ncl.2020.05.001_bib44","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.ncl.2020.05.001_bib45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.ncl.2020.05.001_bib46","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP(+) and anti-HMGCR(+)myopathies: Role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ncl.2020.05.001_bib47","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ncl.2020.05.001_bib48","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/BOR.0000000000000555","article-title":"Antisynthetase syndrome pathogenesis: knowledge and uncertainties","volume":"30","author":"Gallay","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.ncl.2020.05.001_bib49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CPM.0000000000000171","article-title":"The diagnosis and treatment of antisynthetase syndrome","volume":"23","author":"Witt","year":"2016","journal-title":"Clin Pulm Med"},{"issue":"8","key":"10.1016\/j.ncl.2020.05.001_bib50","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal muscle involvement in antisynthetase syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2020.05.001_bib51","first-page":"100","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J\u00a0Bras Pneumol"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:18:04Z","timestamp":1760005084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861920300396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0733861920300396"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2020.05.001","relation":{},"ISSN":["0733-8619"],"issn-type":[{"type":"print","value":"0733-8619"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory Myopathies","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}